Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial
François Quénet(Institut de Recherche en Cancérologie de Montpellier), Patrick Rat(Université Claude Bernard Lyon 1), Denis Pezet(Centre Hospitalier Universitaire de Clermont-Ferrand), Valeria Loi(Sorbonne Université), J Paineau, Olivier Gléhen(Hospices Civils de Lyon), Diane Goèré(Assistance Publique – Hôpitaux de Paris), Hélène de Forges(Université de Montpellier), Pierre Méeus(Centre Léon Bérard), Béata Juzyna(UniCancer Group), Laurent Ghouti(Centre Hospitalier de Saint-Malo), Olivier Facy(Maison des Sciences sociales et des Humanités de Dijon), C. Arvieux(Université Grenoble Alpes), Marc Pocard(ParisTech), Guillaume Portier, Cécile Brigand, Jean-Marc Bereder, Dominique Élias(Institut Gustave Roussy), Lise Roca(Université de Montpellier), Simon Msika(Hôpital 20 Août), G. Lorimier(Centre de recherche Paul Pascal), Frédéric Marchal(Institut de Cancérologie de Lorraine), Pascale Mariani(Université Paris Sciences et Lettres)
Cited by 812
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.3k
Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype
|Gut|2014|483
Colonization of the Human Gut by <i>E. coli</i> and Colorectal Cancer Risk
|Clinical Cancer Research|2013|482